Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trabedersen - Autotelic/Oncotelic Therapeutics

Next Previous
X
Search
Drug Profile

Trabedersen - Autotelic/Oncotelic Therapeutics

Alternative Names: AP 2/09-DS; AP-12009; AP-2/09; OT-101; OT-201; Personalised dosing TGF-beta antisense; TGF-beta antisense

Latest Information Update: 04 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antisense Pharma
  • Developer Autotelic; Isarna Therapeutics; Mateon Therapeutics; Oncotelic; Oncotelic Therapeutics; Oncotelic Therapeutics - Dragon Overseas Capital (JV)
  • Class Antineoplastics; Antisense oligonucleotides; Antivirals; Immunotherapies; Oligodeoxyribonucleotides; Thionucleotides
  • Mechanism of Action Transforming growth factor beta2 inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II/III Malignant melanoma; Pancreatic cancer
  • Phase I/II Colorectal cancer
  • Phase I Cancer
  • Clinical Phase Unknown Non-small cell lung cancer
  • Preclinical Diffuse intrinsic pontine glioma
  • No development reported COVID 2019 infections; COVID-19 pneumonia; Ovarian cancer
  • Discontinued Anaplastic astrocytoma

Most Recent Events

  • 02 Sep 2024 University of Nebraska plans a phase I/II trial for Non-small cell lung cancer (Combination therapy, First-line therapy or greater, Metastatic disease, Late-stage disease) in USA (IV) (NCT06579196)
  • 11 Jun 2024 Pharmacokinetics and pharmacodynamics data from a phase I/II trial in Solid tumour released by Oncotelic Therapeutics
  • 28 Apr 2024 No recent reports of development identified for preclinical development in COVID-19 pneumonia in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top